Press Releases


LyGenesis logo.png

LyGenesis Closes $3 Million Series A Financing to Advance Its Organ Regeneration Technology to the Clinic

Pittsburgh, PA, May 9, 2018 – LyGenesis, Inc., a biotechnology company developing innovative technology for organ regeneration, announced today that they have raised $3 million in Series A financing from Juvenescence, Ltd. LyGenesis’ technology uses lymph nodes as bioreactors to regrow functioning organs within a patient’s own body. The financing will enable LyGenesis to complete the final preclinical work required to enable human clinical trials, which will initially focus on patients with end stage liver disease.